["AMM updates" section of the journal Bulletin du Cancer: Feedback from the contributing authors]

Since 2020, the "marketing authorization updates" section of Bulletin du Cancer has provided a monthly educational summary of new marketing authorizations (MAs) granted by the European Medicines Agency (EMA) in the fields of oncology and hematology. A survey was conducted five years after its creation to assess the functioning of the format, its informative and educational value, and potential areas for improvement.

An online questionnaire comprising 16 items was distributed in May 2025 to the 245 authors who had contributed to at least one article in the AMM section.

A total of 78 responses were collected, including 52 residents and 26 senior physicians. The results were positive regarding the organization and the quality of interactions within the author pairs, with writing guidelines rated as "clear" or "perfectly clear" in over 80% of responses. The perceived educational value was high for both trainees and seniors (median self-reported educational benefit of 9/10 for residents and 7.5/10 for senior physicians). Overall satisfaction with the format was also high, with a median rating of 9/10 in both groups.

This survey highlights the value of the "marketing authorization updates" section, which successfully fulfils a dual mission of education and information, while fostering intergenerational collaboration.